| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2029-11-21 |
| Par Value | 1000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 62.52 |
| Coupon | 3.2 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 5500 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Abbvie Inc corporate note has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million USD and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
AbbVie Inc, founded in 2013 and headquartered in North Chicago, Illinois, is a global biopharmaceutical company dedicated to the development and commercialization of innovative therapies. The company focuses on various therapeutic areas, including immunology, oncology, neuroscience, and virology, with flagship products such as Humira and Imbruvica contributing significantly to its portfolio.